Global Androgen Antagonist Market Growth (Status and Outlook) 2023-2029

Global Androgen Antagonist Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Androgen Antagonist Industry Forecast” looks at past sales and reviews total world Androgen Antagonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Androgen Antagonist sales for 2023 through 2029. With Androgen Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Androgen Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Androgen Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Androgen Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Androgen Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Androgen Antagonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Androgen Antagonist.
The global Androgen Antagonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Androgen Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Androgen Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Androgen Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Androgen Antagonist players cover Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Merck, Sanofi, Orion Corporation, Hengrui and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Androgen Antagonist market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Steroidal Androgen Antagonist
Nonsteroidal Androgen Antagonist
Segmentation by application
Prostate Cancer
Benign Prostatic Hyperplasia
Polycystic Ovary Syndrome (POCS)
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Merck
Sanofi
Orion Corporation
Hengrui
Bayer
Schering-Plough
Hinova Pharma
Jiangsu Hengrui Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.